[Hyperlipidemia and hyperglycemia prevalence in obese children: increased risk of cardiovascular disease?]

M Marcano1, L Solano, M Pontiles

  • 1Centro de Investigaciones en Nutrición Dr. Eleazar Lara Pantin, Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela. marcanom@uc.edu.ve

Nutricion Hospitalaria
|August 18, 2006
PubMed

Insights

Obese children in Venezuela show high cardiovascular disease risk due to abnormal lipid profiles, particularly low HDL-C and high triglycerides. Early intervention with dietary changes and increased physical activity is crucial for prevention.

Area of Science:

  • Pediatrics
  • Cardiovascular Health
  • Metabolic Disorders

Background:

  • Cardiovascular diseases are the leading cause of mortality in Venezuela.
  • Early signs of coronary atherosclerosis are linked to childhood obesity and diabetes.
  • Preventive strategies should target children to mitigate long-term risks.

Purpose of the Study:

  • To investigate the prevalence of hyperlipidemia and hyperglycemia in obese children.
  • To identify early indicators of cardiovascular disease risk in pediatric populations.
  • To assess metabolic risk factors in relation to obesity in children.

Main Methods:

  • Studied 121 obese children (BMI > 90th percentile) aged 8.7 ± 3.43 years.
  • Measured serum lipids (cholesterol, HDL-C, LDL-C, triglycerides) and fasting glucose.
  • Utilized established cut-off points for risk assessment and analyzed data by age and gender.

Main Results:

  • Elevated cholesterol and triglycerides were observed in specific age and gender groups.
  • Low levels of HDL-C were prevalent in both girls and males across different age groups.
  • No cases of hyperglycemia were detected, but many children met criteria for Metabolic Syndrome.

Conclusions:

  • Obese children exhibit concerning lipid profiles (low HDL-C, high triglycerides), indicating significant cardiovascular disease risk.
  • Males, particularly in older age groups, were more affected by lipid abnormalities.
  • Implementing dietary modifications and promoting physical activity is essential for managing Metabolic Syndrome and preventing cardiovascular disease in children.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...